A reported federal cancer-vaccine initiative lifted Moderna and other vaccine makers, and analysts said it bodes well for oncology immunotherapy developers.

Multiple outlets reported a new FDA-approved weight-loss treatment, as attention also focused on the regulatory status of experimental obesity drugs such as ret

The Korean biotech refiled its liver cancer application after an earlier FDA setback, a key regulatory test for its oncology franchise.

The approval gives patients with drug-resistant herpes simplex virus a new oral antiviral option.

The long-acting injectable offers schizophrenia patients a monthly subcutaneous alternative to existing olanzapine formulations.

The agency cleared a new therapy for one of the deadliest tumor types, where treatment options remain limited.

The approval moves a university-discovered compound into the clinic for Parkinson's disease patients.

The company stopped the programs after failing to fund a Phase 3 trial, a setback for allogeneic cell therapy.

Analysts pointed to continued opportunities in immuno-oncology after the Moderna-Merck cancer vaccine readout.

Positive late-stage data supports the company's push in a rare genetic disease.

The gene-editing developer outlined a busy second-half pipeline, lifting shares in after-hours trading.

The China-based study tests the bispecific antibody in earlier-stage colon cancer patients.

The Institute of Cancer Research study aims to overcome a common barrier to checkpoint inhibitor response.

Long-term follow-up adds evidence for immunotherapy in a subset of colorectal cancer patients.

Patent expirations on major biologics are opening a large market for copycat versions.

The European clearance expands immunotherapy into an aggressive, hard-to-treat cancer.

The mid-stage or late-stage data adds to Lilly's oral obesity pipeline as competition intensifies.

The cell and gene therapy CDMO pointed to revenue growth as evidence of a turnaround.